News

AFT makes further progress in international markets

AFT Pharmaceuticals provides an update on recent progress it has made in international markets.

Read More

AFT updates operating profit guidance to $23m to $25m

AFT Pharmaceuticals today announces an update to guidance for the financial year to the end of March 2024 (FY24).

Read More

MAXIGESIC® SPONSORS THE ONE NZ WARRIORS

AFT Pharmaceuticals announces Maxigesic® is the new Official Pain Relief Partner of the One New Zealand Warriors for the 2024 and 2025 NRL seasons.

Read More

Maxigesic IV launched in the United States

AFT Pharmaceuticals announces Maxigesic IV®, the patented intravenous form of its family of pain relief medicines, has today been launched in the US by its licensee Hikma Pharmaceuticals.

Read More

AFT further broadens R&D pipeline with new product candidate for Vulva Lichen Sclerosus

AFT Pharmaceuticals announces it has entered into a further partnership with one of its long-standing research and development partners, Belgium’s Hyloris Pharmaceuticals to develop a novel treatment for the management of the skin condition Vulvar Lichen Sclerosus (VLS) where there is limited availability of approved treatments.

Read More

AFT poised to accelerate momentum in 2024

As the new year commences, AFT Pharmaceuticals is looking forward to building upon the significant progress made during 2023. Last year we moved on from the uncertainties of the COVID-19 pandemic and we are pleased with the progress we made, especially in our international markets.

Read More

AFT broadens R&D pipeline with new product candidate in Burning Mouth Syndrome

AFT Pharmaceuticals today announces that it has entered into a partnership with one of its research and development partners, Belgium’s Hyloris Pharmaceuticals to develop a novel locally acting product for the treatment of Burning Mouth Syndrome (BMS).

Read More

AFT Pharma reports growth and global expansion

FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2023

Read More

AFT welcomes US FDA approval for sale of Maxigesic IV®

AFT Pharmaceuticals announces the US FDA has approved Maxigesic IV®, the intravenous form of its patented pain relief medicine, for sale in the US, which represents AFT’s second FDA approval within one year.

Read More

AFT Pharmaceuticals to announce half year interim results

AFT Pharmaceuticals announced today that it intends to release on Thursday November 23 2023 its half year interim results for the period ended September 30 2023.

Read More

AFT appoints Andrew Lane as independent director

AFT Pharmaceuticals today announces the appointment of Andrew Lane as an independent non-executive director.

Read More

Retirement of Jon Lamb

Independent director Jon Lamb today retired from the board following his announcement at the ASM.

Read More